BioPharma Credit (BPCR) Competitors GBX 0.88 +0.00 (+0.23%) As of 07/4/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock BPCR vs. ATST, ABDN, 3IN, PHLL, JGGI, RCP, BUR, BPT, MNKS, and EMGShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Alliance Trust (ATST), abrdn (ABDN), 3i Infrastructure (3IN), Petershill Partners (PHLL), JPMorgan Global Growth & Income (JGGI), RIT Capital Partners (RCP), Burford Capital (BUR), Bridgepoint Group (BPT), Monks (MNKS), and Man Group (EMG). These companies are all part of the "asset management" industry. BioPharma Credit vs. Its Competitors Alliance Trust abrdn 3i Infrastructure Petershill Partners JPMorgan Global Growth & Income RIT Capital Partners Burford Capital Bridgepoint Group Monks Man Group Alliance Trust (LON:ATST) and BioPharma Credit (LON:BPCR) are both financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Which has more volatility and risk, ATST or BPCR? Alliance Trust has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Does the media refer more to ATST or BPCR? In the previous week, Alliance Trust's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score. Company Overall Sentiment Alliance Trust Neutral BioPharma Credit Neutral Is ATST or BPCR a better dividend stock? Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 795.5%. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Which has better valuation and earnings, ATST or BPCR? BioPharma Credit has higher revenue and earnings than Alliance Trust. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlliance Trust£652.76M0.00£601.66M£2.12N/ABioPharma Credit£12.99B0.08£10.42B£0.0910.00 Is ATST or BPCR more profitable? Alliance Trust has a net margin of 92.17% compared to BioPharma Credit's net margin of 80.20%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.Company Net Margins Return on Equity Return on Assets Alliance Trust92.17% 17.93% 10.95% BioPharma Credit 80.20%8.51%4.98% Do institutionals and insiders believe in ATST or BPCR? 6.9% of Alliance Trust shares are owned by institutional investors. Comparatively, 41.5% of BioPharma Credit shares are owned by institutional investors. 2.4% of Alliance Trust shares are owned by insiders. Comparatively, 6.2% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryAlliance Trust beats BioPharma Credit on 7 of the 12 factors compared between the two stocks. Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£1.04B£1.25B£6.37B£2.96BDividend Yield13.43%4.36%4.17%5.02%P/E Ratio10.0021.8113.47147.88Price / Sales0.082,406.261,784.55258,917.23Price / Cash1.1960.8148.8327.97Price / Book0.011.211.404.61Net Income£10.42B£264.68M£1.24B£5.90B7 Day PerformanceN/A0.37%0.56%1.04%1 Month PerformanceN/A2.71%3.26%5.12%1 Year Performance3.04%6.53%15.53%80.81% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.88+0.2%N/A+2.8%£1.04B£12.99B10.00N/AATSTAlliance TrustN/AN/AN/AN/A£3.58B£652.76M600.003ABDNabrdn1.0032 of 5 starsGBX 186.80-0.1%GBX 172-7.9%+20.8%£3.34B£1.49B10.624,719News Coverage3IN3i InfrastructureN/AGBX 333.74-1.6%N/A+4.5%£3.08B£374M878.27N/ANews CoveragePHLLPetershill Partners1.8529 of 5 starsGBX 226.50+2.5%GBX 240+6.0%+11.9%£3.08B£706.00M9.19N/ANews CoverageJGGIJPMorgan Global Growth & IncomeN/AGBX 549+0.2%N/A-4.8%£2.83B£660.56M4.52N/ANews CoverageRCPRIT Capital PartnersN/AGBX 1,940.50-1.3%N/A+3.5%£2.80B£103.46M16.7762News CoverageBURBurford Capital3.2367 of 5 starsGBX 949.50-0.6%GBX 1,600+68.5%-0.1%£2.61B£299.55M16.99140News CoverageBPTBridgepoint Group2.1072 of 5 starsGBX 312.46-1.5%GBX 359.33+15.0%+31.7%£2.58B£272.35M56.76391News CoverageAnalyst ForecastGap UpMNKSMonksN/AGBX 1,298flatN/A+11.4%£2.50B£610.03M4.21N/ATrending NewsEarnings ReportEMGMan Group2.3089 of 5 starsGBX 172.90+0.3%GBX 278+60.8%-29.5%£2.50B£1.69B8.161,790News Coverage Related Companies and Tools Related Companies Alliance Trust Alternatives abrdn Alternatives 3i Infrastructure Alternatives Petershill Partners Alternatives JPMorgan Global Growth & Income Alternatives RIT Capital Partners Alternatives Burford Capital Alternatives Bridgepoint Group Alternatives Monks Alternatives Man Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BPCR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
